This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Nyxoah SA (NYXH) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nyxoah (NYXH) delivered earnings and revenue surprises of -2.22% and 56.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Clover Health Investments, Corp. (CLOV) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Clover Health Investments (CLOV) delivered earnings and revenue surprises of 125% and 5.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
CareCloud, Inc. (CCLD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
CareCloud (CCLD) delivered earnings and revenue surprises of 93.75% and 2.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Privia Health (PRVA) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of -60% and 4.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Inspire Medical Systems (INSP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 46.03% and 1.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Nyxoah SA (NYXH) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nyxoah SA (NYXH) delivered earnings and revenue surprises of 0% and 2.39%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 13.33% and 10.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Nextgen Healthcare (NXGN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of 24% and 0.20%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Nyxoah SA (NYXH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nyxoah SA (NYXH) delivered earnings and revenue surprises of -8.89% and 15.64%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 0% and 8.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Nyxoah SA (NYXH) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nyxoah SA (NYXH) delivered earnings and revenue surprises of -32.43% and 61.23%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Lineage Cell (LCTX) delivered earnings and revenue surprises of 0% and 21.41%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health (SYNH) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 11.94% and 6.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Senseonics (SENS) delivered earnings and revenue surprises of 0% and 35.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Privia Health (PRVA) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of 100% and 2.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Nyxoah SA (NYXH): Can Its 10.2% Jump Turn into More Strength?
by Zacks Equity Research
Nyxoah SA (NYXH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Wall Street Analysts See a 240% Upside in Nyxoah SA (NYXH): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Nyxoah SA (NYXH) points to a 240% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Nyxoah SA (NYXH) Could Rally 170%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Nyxoah SA (NYXH) points to a 170.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CareCloud, Inc. (MTBC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CareCloud, Inc. (MTBC) delivered earnings and revenue surprises of 46.15% and 0.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Nyxoah SA (NYXH) Stock Jumps 13.2%: Will It Continue to Soar?
by Zacks Equity Research
Nyxoah SA (NYXH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Computer Programs and Systems (CPSI) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Computer Programs and Systems (CPSI) delivered earnings and revenue surprises of 22.73% and 3.85%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Nyxoah (NYXH) Ahead of Earnings?
by Zacks Equity Research
Nyxoah (NYXH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should You Buy Nyxoah (NYXH) Ahead of Earnings?
by Zacks Equity Research
Nyxoah (NYXH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.